Tuesday, February 28, 2017

Sovaldi/Harvoni/ Epclusa - How Gilead’s Revenue Trended in 2016

Thought this was interesting..

Investment Commentary @ Market Realist

How Gilead’s Liver Disease Drugs Portfolio Performed
By Mike Benson | Feb 28, 2017 5:54 pm EST

How Gilead’s Revenue Trended in 2016
Part 4

Epclusa is a new drug for the treatment of chronic Hepatitis C infection of Genotype-1 to Genotype-6 with or without cirrhosis. For patients who have advanced cirrhosis, the drug is used in combination with Ribavirin. Epclusa will be a new blockbuster drug for the treatment of patients with Hepatitis C infections. The drug reported revenues of $1.8 billion for 2016.

So what about Sovaldi and Harvoni, find out here...

Complete article; Why Gilead’s Valuation Is Low Compared to Peers

In Case You Missed It
Hepatitis C Virus Drug Costs Likely to Fall
Laurie Toich, Assistant Editor
Publish Date: Tuesday, February 07, 2017

The high cost of hepatitis C virus (HCV) drugs has caused significant financial strain for patients and the health care system. These drugs cost as much as $95,000 for a 12-week treatment, but carry a 90% or better cure rate, which many believe justifies the cost.

While some insurers have implemented cost containment strategies to prevent early stage patients from receiving the treatment, lawsuits have been filed challenging the ethics of these practices.

Lawmakers are now struggling to create legislation that will provide these patients with the treatments they need, but a majority of proposals do not gain traction, according to a report published by Mediware.

Continue reading, page 1, page 2...

Updates - February 2017
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

No comments:

Post a Comment